Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHO-H02
- Development stage
- Preclinical
- Lead developer
- Cho Pharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CHO-H02 is a next-generation monoclonal antibody drug candidate targeting HER2 (receptor protein-tyrosine kinase erbB-2), an oncogenic receptor highly expressed in various solid tumors, including breast, bladder, pancreatic, ovarian, and gastric cancers. Developed using glycoengineering technology by CHO Pharma and originally by Academia Sinica, the project includes both glycoengineered biobetter antibodies and antibody-drug conjugates (ADCs) designed to enhance anti-tumor efficacy. The mechanism of action involves antagonism of the HER2 receptor. As of early 2025, CHO-H02 is in preclinical development with IND-enabling studies underway for a phase 1 clinical trial[1][2].
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on CHO-H02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHO-H02.